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Aim. To investigate the role of maximum tumour diameter (D-max) reduction rate at CT examination in predicting
histopathological tumour regression grade (TRG according to the Becker grade), after neoadjuvant chemotherapy (NAC), in
patients with resectable advanced gastric cancer (AGC). Materials and Methods. Eighty-six patients (53 M, mean age 62.1 years)
with resectable AGC (≥T3 or N+), treated with NAC and radical surgery, were enrolled from 5 centres of the Italian Research
Group for Gastric Cancer (GIRCG). Staging and restaging CT and histological results were retrospectively reviewed. CT
examinations were contrast enhanced, and the stomach was previously distended. The D-max was measured using 2D software
and compared with Becker TRG. Statistical data were obtained using “R” software. Results. The interobserver agreement was
good/very good. Becker TRG was predicted by CT with a sensitivity and speciﬁcity, respectively, of 97.3% and 90.9% for Becker
1 (D-max reduction rate> 65.1%), 76.4% and 80% for Becker 3 (D-max reduction rate< 29.9%), and 70.8% and 83.9% for
Becker 2. Correlation between radiological and histological D-max measurements was strongly conﬁrmed by the correlation
index (c.i.= 0.829). Conclusions. D-max reduction rate in AGC patients may be helpful as a simple and reproducible radiological
index in predicting TRG after NAC.
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1. Introduction
In the Western world, almost two-thirds of patients with
gastric cancer (GC) have locally advanced tumours (stage
IIIA or B, or IV) at the time of diagnosis with a less than
50% chance of radical surgery [1, 2]. For this reason,
neoadjuvant chemotherapy (NAC) has been introduced
successfully in the treatment of locally advanced gastric
adenocarcinoma in the United States and Europe, improv-
ing both progression-free survival (PFS) and overall sur-
vival (OS) over surgery alone in patients with operable
tumours [3–5].
Even if long-term outcomes of patients with advanced
gastric cancer (AGC) remain poor despite multimodality
treatment [6, 7], patients with clinical response to NAC
have a signiﬁcantly better prognosis than nonresponding
patients. For this reason, preoperative identiﬁcation of
responder patients, as well as methods for predicting
the outcome of patients submitted to NAC, is crucial in
order to provide prognostic information to patients and
guide clinicians in further surgical and/or adjuvant treat-
ments [8, 9].
In this sense, histopathological regression (HPR) after
chemotherapy is believed to be an important objective
parameter of response to therapy and the tumour regres-
sion grade (TRG) was ﬁrst described as a measure of his-
tologic response in gastric cancer patients by Becker et al.,
who observed histopathological changes in surgical speci-
mens treated with NAC compared with resected cancers
from patients treated with surgery alone [10]. The clinical
and prognostic values of TRG have been demonstrated in
several small studies, and, more recently, it was found to
be an independent prognostic factor in a large series of
GCs by the same group. In any case, histological response
to NAC is shown in just a minority of such GC patients;
furthermore, about 30% of patients with an evident HPR
of the primary tumour still die due to recurrence. Thus,
the histopathological response to chemotherapy is still
not clearly deﬁned, and its predictive value and clinical
application in GC remain unclear [11–15]. On this basis,
there is an unmet need for a possible role of imaging in
the prediction of chemotherapy response and/or in the
early identiﬁcation of nonresponder from responder
patients, to prevent ineﬀective and potentially harmful
treatment in nonresponders. In addition, emerging imag-
ing methodologies for achieving this goal are not always
reproducible and easy to use [8, 16–19].
The purpose of our study is therefore to investigate the
feasibility of GC maximum tumour diameter (D-max)
reduction rate at CT examination as an eﬀective, easy to
use, and reproducible radiological index in predicting
TRG after NAC. This multicentre study was conducted by
the Italian Research Group for Gastric Cancer (GIRCG), a
multidisciplinary research group including clinicians (sur-
geons, pathologists, gastroenterologists, medical oncologists,
radiologists, nutritionists, and statisticians) with recognised
expertise in GC diagnosis, care, and research from over 25
specialised centres in Italy.
2. Materials and Methods
2.1. Patients. This study was approved by the institutional
review boards of our hospitals, and written informed consent
was obtained from all subjects. Abdominal CT examinations
of 86 patients were retrospectively reviewed from a cohort of
103 consecutive patients treated with NAC followed by
gastrectomy in 5 GIRCG centres (Siena, Forlì, Monte-
varchi, Brescia, and Verona), between January 2010 and
June 2017. Inclusion criteria consisted of biopsy-proven,
locally-advanced GC without distant metastases (i.e., clinical
parameters T≥ 3 and/or N+, M0). Seventeen out of 103
patients were excluded because of an interval between CT
and surgery longer than 45 days (n = 3), presence of metasta-
tic disease at restaging CT (n = 4), neoplastic involvement of
the esophagus (n = 2), clinical complications during chemo-
therapy needing urgent surgery (n = 3), and inappropriate
CT methodology or technical parameters (stomach not dis-
tended or slice thickness ≥5mm, n = 5). All the 86 patients
included in the study (53 men and 33 women, mean age
62.1 years, range 26.7–78) underwent staging CT examina-
tion before NAC and a restaging CT performed within a
maximum period of 45 days (mean 26 days, range: 1–45)
from surgery; sixteen out of 86 patients also underwent an
intermediate CT examination after 2 cycles of chemotherapy
(early assessment; CT1 pre-NAC, CT2 intermediate, and
CT3 presurgical), totalling to 188 examinations. Diﬀerent
chemotherapy regimens are reported in Table 1.
2.2. CT Imaging Protocol. CT scans (CTs) were obtained
using a 64-detector row conﬁguration (LightSpeed Plus and
VCT, General Electric Healthcare, Milwaukee, USA) for 40
patients, a 16-detector row conﬁguration (LightSpeed 16
Pro, General Electric Healthcare, Milwaukee, USA) for 19
patients, a 32-detector row conﬁguration (VCT, General
Electric Healthcare, Milwaukee, USA) for 18 patients, and a
128-detector row conﬁguration (Somatom Deﬁnition Flash
DE, Siemens) for the remaining 9 patients (Table 2). All
patients who underwent the CTs had fasted for 8 hours.
CTs, acquired with a spiral technique, were preceded by
stomach distension obtained with air or water; the stomach
was considered distended when gastric folds appeared mostly
ﬂat in the tumour location. To avoid possible bias in measur-
ing tumour D-max, the same technique of stomach inﬂation
Table 1: Diﬀerent chemotherapy regimens of all patients.
Chemotherapy regimen
Patients
(number)
ECF (epirubicin, cisplatin, and 5-ﬂuorouracil) 16
DOX (docetaxel, oxaliplatin, and capecitabine) 46
EOX (capecitabine, oxaliplatin, and ED epirubicin) 7
DCF (docetaxel, cisplatin, and 5-ﬂuorouracil) 2
2ECF+ 4DCF 1
CDDP(cisplatin) + capecitabine 1
FOLFOX (folic acid, ﬂuorouracil, and oxaliplatin) 9
1 DOX+3DOF (docetaxel, oxaliplatin, and ﬂuorouracil) 1
EOF (epirubicin, oxaliplatin, and 5-ﬂuorouracil) 3
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was used both in staging and restaging CTs for each patient.
Air distension was obtained by administering per os two
pouches of eﬀervescent granules, together with 10ml of
water, 3 minutes before the scan, whereas in the second
method (water distension), the patient was requested to
drink 3 or 4 glasses (125ml) of water immediately before
CT examination. All patients also received 1mg of glucagone
(Glucagen, Novo Nordisk) or 20mg of hyoscine butylbro-
mide (Buscopan, Pharmamedix) intravenously injected to
induce gastric hypotonia. After a scout view, an unenhanced
upper abdominal CT scan was acquired from the dia-
phragmatic domes to 2 cm below the lower margin of
the gastric body to conﬁrm the distension of the stomach.
Contrast-enhanced CTs were performed in the late arterial
phase (start delay 45–50 s) in the upper abdomen and in
the portal venous phase (start delay 70–80 s) from the pel-
vic brim to the thoracic inlet, after an intravenous injec-
tion of 2mL/kg of nonionic contrast material (iodine
concentration≥ 350mg/ml), followed by 40mL of saline
solution, using a semiautomated power injector (3,5–4mL/s
ﬂow rate) with an 18/20-gauge needle in the antecubital vein.
A delayed CT scan after 5 minutes was used to characterise
uncertain liver lesions. The CT technical parameters are
reported in Table 3. An automatic current modulation
tube was used to minimise radiation exposure. A standard
reconstruction algorithm was used, and patients were
instructed not to breathe during helical imaging to avoid
motion artefacts.
2.3. Image Analysis. All 188 CT examinations (140 for 70
patients and 48 for 16 patients) were analysed in the arterial
late phase on a reconstruction and image interpretation con-
sole (Advantage Workstation 4.1/3, GE) adjusting the
image’s level, window and enlargement values each time,
and routinely using a 2D multiplanar reconstruction tech-
nique (coronal, sagittal, and oblique planes). Images were
independently reviewed by two blinded readers, a resident
radiologist and a radiologist with 4- and 15-year experience
in abdominal CT, respectively (FG and MAM). Readers were
asked to review the images of each patient in a random man-
ner, avoiding the date on which they were performed,
tumour histotype, and HPR. Maximum tumour diameter
(D-max), enhancement of the lesion, and depth of tumour
invasion (T parameter) were evaluated. D-max was measured
using a curved line through 2D multiplanar reconstructions
in order to obtain the maximum tumour extension; all the
possible diﬀerent planes were evaluated for each exam
because of the diﬀerent positioning of the stomach between
the diﬀerent CTs and/or changed orientation of maximum
tumour diameter in case of response to NAC (Figure 1); if
the lesion was small and ulcerated, D-max was acquired mea-
suring ulcer contour, according to histopathological proce-
dures. Regarding enhancement of the lesion, the ratio
between Hounsﬁeld unit (HU) values of the lesion and the
aorta in the late arterial phase was calculated to avoid errors
arising from small diﬀerences in the scan timing from con-
trast agent injection or dissimilar quality/amount of the con-
trast agent. For this purpose, a region of interest (ROI), as
large as possible with a minimum area of 9mm2, was placed
over the lesion and another ROI was placed over the aorta
(minimum area of 20mm2). The T parameter was evaluated
using all the postcontrast phases available, distinguishing
T≥ 3 from T≤ 2, according to CT criteria for T staging of
the AJCC cancer staging manual (8th edition) and based on
the concept that the normal gastric wall is typically seen as
a three-layered pattern on the contrast-enhanced CT images
[18]. Any disagreement was discussed until a consensus was
reached. Finally, the results regarding the D-max and T
parameters were compared with the histological data after
surgery, in particular, correlating the D-max reduction rate
at restaging CT to histological TRG.
2.4. Surgical Features. General preoperative indications for
treatment were histological diagnosis of GC obtained with
upper digestive endoscopy and biopsy and the absence of dis-
tant metastases. A staging laparoscopy with cytology on peri-
toneal washing was performed in 47 out of 86 patients, in
order to exclude the presence of peritoneal metastases. The
surgical procedure was performed according to GIRCG
guidelines [4]. For tumours located in the middle and lower
Table 2: List of tomographs adopted in the study.
GIRCG center Tomograph Layers Patients (number)
Siena VCT, GE Healthcare 64 32
Forlì LightSpeed Pro, GE Healthcare 16 19
Montevarchi LightSpeed Pro, GE Healthcare 32 18
Brescia Siemens Somatom Deﬁnition Flash DE 128 9
Verona LightSpeed, GE HealthCare 64 8
Table 3: CT technical parameters. Slice thickness is reported for the
late arterial phase.
CT technical parameters
Slice thickness (mm) Patients (number)
1.25 30
2 20
2.5 17
3.75 8
Beam pitch 0.9/1.3
Reconstruction interval (IR)
At least half of the eﬀective
slice thickness
Tube voltage (kVp) 120–140
Reference mAs 200/250–500/600
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third of the stomach, a subtotal gastrectomy was generally
preferred with an adequate proximal resection margin. In
all other cases, total gastrectomy with Roux-en-Y reconstruc-
tion was the preferred procedure. The gastrectomy was com-
pleted by bursectomy and removal of the greater omentum
and regional lymph nodes (LNs) [20, 21]. Systematic removal
of LN station numbers 7 (left gastric artery), 8a and 8p
(common hepatic artery), 9 (celiac artery), 11 (splenic
artery), 12a and 12p/b (hepatoduodenal ligament), 13 (retro-
pancreatic), and 14v (superior mesenteric vein) was per-
formed, whereas station 10 (splenic hilum) was removed
optionally. With reference to the paraaortic area, after the
Kocher manoeuvre, the resection of nodes between the level
of the celiac axis and the left renal vein (station 16-a2) and
nodes between the left renal vein and the inferior mesenteric
artery (station16-b1) was performed optionally [22]. Sple-
nectomy was performed only in the case of direct involve-
ment by the tumour, or in tumours located in the proximal
greater curvature. Following surgery, single LNs were
retrieved on the fresh specimen by the surgeon and classiﬁed
in Japanese Research Society for Gastric Cancer (JRSGC)
nodal stations for pathological examination [23].
2.5. Pathological Analysis. Histopathological ﬁndings were
evaluated by expert gastrointestinal pathologists. At the mac-
roscopic examination, tumours were classiﬁed according to
the criteria proposed by Borrmann into polypoid, fungating,
ulcerated, and inﬁltrative [24]. The tumour location was clas-
siﬁed as upper, upper/middle, middle, middle/lower, and
lower third. The maximum tumour size was performed mea-
suring the residual tumour extension and the scarring area of
the precedent tumour (tumour bed), and macroscopic dis-
tance of the lesion from the proximal and distal surgical mar-
gins was reported.
At least ﬁve tissue blocks from the tumour site were taken
if tumour was grossly visible; if the viable tumour was not
grossly evident, the whole suspicious area was embedded
with step sectioning at 5mm [13]. Antrum and body samples
were collected, and proximal and distal resection margins
were removed. LNs were distinguished in stations according
to the JRSGC classiﬁcation [23]. Each LN was sectioned on
the plane of the largest size. Sections were embedded in par-
aﬃn, sectioned at 5 microns, and coloured by hematoxylin
and eosin staining.
All the following ﬁndings were reported in the micro-
scopic report according to GIRCG guidelines [4]: WHO
classiﬁcation and grading (WHO 2010), Lauren histotype,
depth of inﬁltration, presence or absence of lymphovascu-
lar and/or perineural invasion, state of resection margins,
chemotherapy-induced alterations, such as replacement of
the tumour by ﬁbrous or ﬁbro-inﬂammatory granulation
tissue, histiocytic reaction with hemosiderin-laden and foamy
macrophages, acellular mucus lakes, cholesterol deposits,
dystrophic calciﬁcations, and vascular changes. Tumour
regression grade (TRG) was evaluated according to the
Becker classiﬁcation as percentage of residual neoplasia in
the macroscopically evaluated tumour bed. TRG1a was
deﬁned as complete tumour regression without residual
tumour; TRG1b as subtotal tumour regression with <10%
residual tumour cells; TGR2 as partial tumour regression with
10–50% residual tumour cells; and TRG3 as minimal or
absent regression with >50% residual tumour cells with or
without signs of treatment eﬀects [10, 13, 25].
The total number of examined lymph nodes, total num-
ber of positive lymph nodes, and the topography of examined
and positive lymph node stations were also reported.
Cancer staging and residual tumour in surgical margins
(R) were classiﬁed according to AJCC 8th edition [1].
2.6. Statistical Analysis. The interobserver agreement was
obtained by applying a Kappa test. The Kappa unit ranged
from 0 (chance agreement) to 1 (total agreement). In partic-
ular, K values were deciphered in the following way: K< 0.20,
poor agreement; K=0.21–0.40, fair; K=0.41–0.60, moderate;
K=0.61–0.80, good; and K=0.81–1.00, very good. All the
radiological D-max and HU values of gastric lesion and
aorta were provided as the average result of measurements
of each reviewer from each CT examination. CT results were
compared with histological results, in particular lesion size
(D-max), TRG, and depth of tumour invasion (T). Statistical
(a) (b)
Figure 1: (a, b) Staging (a) and restaging (b) CTs after NAC in a 63-year-old male with a mixed GC. D-max was measured in 2
diﬀerent planes, respectively, axial oblique in (a), D-max 83.6mm, and sagittal in (b), D-max 35.1mm, in order to identify the maximum
tumour extension.
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analysis was performed using “R” software (multiplatform
operative system, GPL licence). Radiological D-max investi-
gation was the focus of the statistical analysis. First of all, the
distributions of the D-max values before and after NAC were
studied by Shapiro-Wilk test and QQ-plot elaboration, and,
given the results, we proceeded with a nonparametric
approach; a bootstrap method was used to individuate D-
max mean values before and after neoadjuvant chemother-
apy and diﬀerences were studied graphically and by the
Wilcoxon test. A similar analysis was conducted in order
to investigate diﬀerences in the 16 patients who underwent
intermediate CT using the ANOVA test and, for multiple
comparisons, t test for independent samples and Bonferroni
correction. A p value< 0.05 was considered statistically sig-
niﬁcant. D-max was also investigated in terms of reduction
rate at restaging CT compared with staging CT (in the
entire population and in the population broken down by
histotype), and the correlation between this parameter and
TRG was investigated. In particular, patients were divided
into 3 groups, analogously to the Becker classiﬁcation,
through two successive dichotomous divisions, and the opti-
mal cutoﬀ values were determined through ROC curves anal-
ysis. Lesion enhancement analysis was performed calculating
the ratio between gastric lesion and aorta HU; the ratio
between normalised values obtained before and after NAC
was calculated and plotted versus diﬀerent Becker grades.
Diﬀerences between radiological and pathological measure-
ments of D-max were investigated through nonparametric
regression and Bland-Altman plot, and the exact identiﬁca-
tion of T parameter (T≤ 2 or T≥ 3) was expressed in terms
of sensitivity, speciﬁcity, VPP, VPN, and accuracy.
3. Results
At histopathology, according to the Becker et al. classiﬁca-
tion, 11 patients (12.8%) had a TRG 1, 24 (27.9%) a TRG
2, and 51 (59.3%) a TRG 3, whereas according to the
AJCC classiﬁcation, 31 (36%) patients resulted in T≤ 2
and 55 (64%) T≥ 3. Mean maximum histopathological
tumour diameter was 53.7mm. There was a prevalence
of the Lauren intestinal histotype with 43 intestinal
(53%), 34 diﬀuse (40%), 7 mixed (8%), and 2 nonclassiﬁ-
able (2%) tumours. A good/very good agreement (0.77-1)
was found between the two readers concerning CT ﬁnd-
ings, and the patients with T≥ 3 at histopathological
examination were individuated by CT with a sensibility of
92.73%, speciﬁcity of 64.52%, PPV of 82.26%, NPV of
83.33, and total accuracy of 82.56%. D-max from staging
and restaging CT examinations did not demonstrate a
normal distribution at the Shapiro-Wilk test (p < 0 05) as
reported in QQ plots (Figures 2 and 3) thus, in order to avoid
statistical errors, mean value distribution was calculated
through the bootstrap method resulting in 100.4mm before
and 68.4mm after NAC, respectively. D-max box plots
graphically showed a diﬀerence between the 2 groups, before
and after NAC (Figure 4), which was then conﬁrmed apply-
ing the Wilcoxon test for paired samples (p = 1938 e-06,
statistically signiﬁcant), demonstrating that chemotherapy
induced a reduction in CT-measured D-max. D-max
reduction rate at restaging CT was not signiﬁcantly diﬀerent
between intestinal and diﬀuse histotypes (resp., 66% and
75%, p > 0 05). The optimal cutoﬀ values of D-max reduc-
tion rate at restaging CT, obtained by ROC curve analysis
to identify 3 groups of patients, analogously to the Becker
classiﬁcation, were ≥65.1% (corresponding to TRG 1,
<10% residual tumour cells, with a sensitivity and speciﬁc-
ity of 97.3% 90.9%, resp.) and ≤29.9% (corresponding to
TRG 3, >50% of residual tumour cells, with a sensitivity
and speciﬁcity of 76.4% and 80.0%, resp.) (Figures 5 and 6).
Using the same cutoﬀ values reported above, Becker grade
2 patients were predicted with a sensitivity and speciﬁcity
of 70.8% and 83.9%, respectively (Figure 7).
Lesion enhancement analysis before and after NAC did
not statistically show signiﬁcant diﬀerences in patients with
diﬀerent Becker grades as shown in the box plots and ﬁgures
(Figures 8 and 9). Moreover, D-max reduction rate diﬀer-
ences were investigated in patients who underwent an inter-
mediate CT after 2 cycles of chemotherapy. The comparison
between the D-max reduction rate between CT1 and CT2
(pre-NAC and intermediate CTs, resp.) and between CT2
and CT3 (intermediate and pre-surgical CTs, resp.) resulted
statistically diﬀerent when applying both the ANOVA test
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Figure 2: Distribution of D-max values before neoadjuvant
chemotherapy: QQ plot demonstrates a nonnormal distribution.
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Figure 3: Distribution of D-max values just before surgery: QQ plot
demonstrates a nonnormal distribution.
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and post hoc Student’s t-test (p = 0 00057 between CT1 and
CT2 while p = 0 02 between CT2 and CT3) suggesting that
the major tumour regression occurred after 2 cycles of che-
motherapy (Figure 10).
Finally, correlation between radiological and pathological
D-max measurement was graphically investigated through
nonparametric regression (Figure 11) and strongly conﬁrmed
by the correlation index (c.i. = 0.829); the Bland-Altman
plot conﬁrmed a high agreement between radiological and
pathological D-max measurement methods (Figure 12).
4. Discussion
HPR after NAC has been shown to be an important
objective parameter of improved survival in a high per-
centage of patients aﬀected by GC [13, 25]. Thus, in this
severe disease, frequently diagnosed in an advanced stage
and with poor prognosis, an accurate assessment of
tumour response to chemotherapy is fundamental in
treatment decision-making [26].
In particular, it would be worth identifying responder
patients, prior to surgery, who may beneﬁt from aggressive
multimodal treatments, achieving patient-centred care and
better health care cost management in this way. Nowadays,
the majority of clinical trials evaluating response to cancer
treatment by imaging use the response evaluation criteria
in solid tumours (RECIST) [27, 28]; however, GC lesion
is deﬁned as nonmeasurable by RECIST, given that the
stomach is not a parenchymatous organ [29]. Moreover,
RECIST response criteria seem to underestimate histologi-
cal gastric tumour response [26], so their implementation
is poor. The role of metabolic imaging, like PET, in this
ﬁeld has been investigated in the literature since 2003;
one of the ﬁrst studies by Ott et al. [16], which analysed
44 patients, showed the potential value of this technique
in monitoring the eﬃcacy of NAC in gastric cancer, pre-
dicting histopathological response in 77% of responders
and 86% of nonresponders; however, several later studies
did not conﬁrm these results, and, in fact, it was demon-
strated how the percentage change in maximum SUV did
not signiﬁcantly correlate with the grade of HPR [8, 30].
Moreover, not all gastric tumours, in particular diﬀuse his-
totype and tumour containing mucus, show FDG uptake
thus the results of diﬀerent series are inﬂuenced by a percent-
age of diﬀerent histotypes included in the study population
[31]. Compared with PET imaging, CT is not inﬂuenced by
the limit of the uptake tracer and at the same time allows a
morphological and functional evaluation, the latter through
contrast agent administration, even if the correct methodol-
ogy and choice of technical parameters in performing the
exam are essential prerequisites for obtaining reliable data:
in particular gastric distension of the stomach, a thin eﬀective
slice thickness and tube voltage/reference mAs appropriated
to patient size [32–34]. In this regard, Yoshikawa et al.
reported poor overall accuracy in determining T parameter
after NAC, suggesting that T staging by CT should not be
considered in clinical decision-making [35], but they per-
formed CT scans using a slice thickness of 5–7mm which is
not acceptable, considering the CT technology currently
available. On the other hand, Lee et al. evaluated tumour
response to NAC through CT, analysing the volume reduc-
tion rate of gastric cancer, which was found to be signiﬁcantly
correlated to HPR [8], even if whole tumour volume has to be
extracted manually tracing lesion boundaries for each slice, a
process that is extremely laborious and hardly applicable in
daily clinical practice. The aim of our study was to investigate
the utility of an easily applicable radiological index (D-max)
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Figure 4: Box plot of D-max values before and after NAC.
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Figure 5: ROC curve of D-max reduction rate to predict Becker
grade 1.
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Figure 6: ROC curve of D-max reduction rate to predict Becker
grade 3.
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at CT examinations in predicting HPR after NAC in GC, and
our results showed that D-max reduction rate seems to be
reliable for identifying responder patients, in particular
Becker/TRG 1 patients. Furthermore, the greater D-Max per-
centage reduction after 2 cycles of NAC in patients who
underwent an intermediate CT is an interesting point which
may suggest anticipating surgery in responder patients; this
result should certainly be conﬁrmed in larger series study
even if some suggestions in this sense are already reported
in the literature [36]. More evidence could come from the
survival results of the ongoing randomised phase-II study
by GIRCG, comparing a preoperative versus perioperative
(pre- +post-operative) docetaxel, oxaliplatin, and capecita-
bin (DOX) regimens in patients with locally advanced
resectable GC.
Gastric lesion enhancement analysis did not show sta-
tistically signiﬁcant results for predicting HPR. For that
reason, even an important lesion contrast uptake reduction
after NAC should not be considered highly suggestive of
tumour response. This data clearly contrasts with those
of Liu et al. who adopted HU analysis to evaluate tumour
response according to adapted Choi criteria; since their
results were correlated to PFS and OS, long-term follow-
up of our patients is needed to draw conclusions in this
regard [26].
Some limitations of our study should be noted. First, it
is a retrospective study, although all CT examinations were
reevaluated in a prospective setting. Second, the examina-
tion technique changed during the study period (5 diﬀerent
CT scanners with slightly diﬀerent examination parameters
and little variation of delay scan after contrast material
injection). Third, there is a lack of patient subdivision on
the basis of diﬀerent chemotherapy regimens and there is
a small number of patients. Fourth, in the case of large-
sized lesion, it can be diﬃcult to measure radiological D-
max in a reproducible way despite 2D multiplanar recon-
structions. Finally, the HPR of gastric tumour was not
related to the HPR of lymph nodes, which would be very
important, in particular in T2 tumours. While CT global
accuracy on the N parameter reaches about 90% at staging,
adopting a double size cutoﬀ (5mm for perigastric nodes
and 8mm for extraperigastric nodes), at present, there are
no established criteria with high accuracy for deﬁning
lymph node response to NAC, such as a cutoﬀ size or rate
of size reduction; therefore, given the complexity of the
issue, further studies are needed in this ﬁeld, probably dif-
ferentiating among diﬀerent tumour histotypes [20]. How-
ever, preliminary previous studies have demonstrated that
lymph node HPR seems to be closely related with those
of primary tumours [37].
In conclusion, our results support the use of CT in evalu-
ating gastric cancer response to NAC on the condition that
CT examination is performed using a dedicated protocol
(a)
48.9 mm (2D)
(b)
Figure 7: (a, b) GC cancer of the angulus (diﬀuse histotype) in a 69-year-old woman. TRG 2 was found on ﬁnal pathology after NAC.
Tumour D-max reduction rate (47.5%), between CT before (a) and after NAC (b), correctly identiﬁed TRG.
Becker
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Figure 8: Box plot showing Hounsﬁeld unit (HU) analysis. HUs
were normalised through the ratio between the lesion and aorta
HU. Values in the y-axis were obtained from the ratio between
HU before and after NAC, whereas values in the x-axis show the
Becker grade.
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(a) (b)
Figure 9: (a, b) A 65-year-old man with GC of the antrum (diﬀuse histotype). After NAC (b), lesion enhancement is signiﬁcantly lower than
before (a), whereas D-max is substantially unchanged. Patient was correctly classiﬁed as TRG 3 on ﬁnal pathology.
94.7 mm (2D)
(a) (b)
(c)
Figure 10: (a–c) Comparison between staging CT (a), intermediate (b) and presurgical (c) CTs in a 71-year-old man with GC (intestinal
histotype) located in the antrum and body, along the lesser curvature. It was clear how D-max reduction rate was greater after 2 cycles of
chemotherapy ((a) versus (b), 47.2%) than in the remainder of the treatment ((b) versus (c), 10%).
8 Gastroenterology Research and Practice
and images are analysed by an experienced reader. A pro-
spective, multicentric GIRCG trial is ongoing in order to
obtain deﬁnitive results.
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